Treatment library
Procedure pages and drug monographs covering the UK skin cancer treatment armamentarium — from cryotherapy to checkpoint inhibitors.
Surgical & physical procedures
Mohs micrographic surgery
Frozen-section margin assessment in horizontal sections; gold standard for high-risk facial NMSC.
Reconstruction atlas
Defect-driven flap and graft selection for nasal subunits, lip, eyelid, ear, scalp, hand.
Cryotherapy
Liquid nitrogen for AK, superficial BCC, Bowen's; technique, dosing, pitfalls.
Photodynamic therapy
MAL-PDT for AK, Bowen's, superficial BCC. Field treatment in OTRs.
Radiotherapy
Definitive RT for inoperable BCC/cSCC; adjuvant for high-risk; brachytherapy options.
Locoregional & intralesional therapies
Electrochemotherapy
Bleomycin + electroporation for cutaneous metastases from non-skin primaries and melanoma (NICE IPG446 scope).
T-VEC (talimogene laherparepvec)
Oncolytic HSV-1 + GM-CSF for unresectable stage IIIB–IVM1a cutaneous melanoma (NICE TA410).
Isolated limb infusion / perfusion
Regional melphalan ± TNF-α for in-transit melanoma and limb sarcoma; Wieberdink grading.
Topical & field therapies
Immune checkpoint inhibitors
Pembrolizumab
Adjuvant and metastatic melanoma; NHS England neoadjuvant stage III pathway; cSCC appraisal in development.
Nivolumab
Adjuvant and metastatic melanoma; combined with ipilimumab or relatlimab.
Ipilimumab
Combined with nivolumab for first-line metastatic melanoma.
Cemiplimab
First-line systemic for advanced cSCC unsuitable for curative surgery / RT.
Avelumab
First-line for untreated metastatic Merkel cell carcinoma (TA691).
Targeted & small-molecule
Dabrafenib + trametinib
BRAF-mutant melanoma — adjuvant stage III (TA544) and metastatic.
Encorafenib + binimetinib
Alternative BRAF / MEK pair for metastatic BRAF-mutant melanoma (NICE TA562). Less pyrexia than dabra / trame.
Vismodegib
Locally advanced or metastatic BCC unsuitable for surgery / RT — NICE TA489 not recommended; not routinely NHS-commissioned.
Imatinib
Locally advanced / metastatic DFSP with confirmed COL1A1-PDGFB.
Cutaneous T-cell lymphoma-directed therapies
Total skin electron beam therapy
Stanford six-position technique — conventional 30–36 Gy or low-dose 10–12 Gy for advanced mycosis fungoides.
Extracorporeal photopheresis
Apheresis + 8-MOP + UVA for erythrodermic CTCL (Sézary, MF T4) and chronic GvHD.
Brentuximab vedotin
CD30+ relapsed / refractory cutaneous T-cell lymphoma (TA577).
Mogamulizumab
Mycosis fungoides / Sézary syndrome relapsed or refractory (TA754).
Prevention & chemoprophylaxis
HPV vaccination (OTR pathway)
9-valent vaccine for anogenital cancer prevention in transplant recipients; emerging cSCC role. 3-dose schedule.
Acitretin chemoprophylaxis
0.2–0.5 mg/kg/day for cSCC chemoprevention in high-burden OTRs and XP / Gorlin. Dosing reference and monitoring.